Entry specification
- SKU
- PAL-SEMAX-RUO
- Format
- Lyophilised research material
- Research size
- 5 mg
- Status
- Restricted inquiry
- Purity
- Research grade, batch documented
- Classification
- Synthetic ACTH(4–7)-derived heptapeptide analogue
Documentation
Documents associated with this entry
Batch record
Analytical summary
Handling note
Linked profile
Semax research context
Semax is a synthetic heptapeptide derived from ACTH(4–7), most extensively characterised in rodent models of cerebral ischaemia and in vitro neurobiology assays. Approved in the Russian Federation as a research and clinical compound; not approved for human therapeutic use in the United States, United Kingdom, or European Union.
Rodent cerebral ischaemia models
Neurochemical gene-expression studies
Copper / amyloid in vitro assays
Peptide stability comparisons
Related reading
How Peptides Are Studied
An introduction to common laboratory approaches used to evaluate peptide behaviour.
6 min
Read article